![Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis | American Society of Nephrology Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis | American Society of Nephrology](https://kidney360.asnjournals.org/content/kidney360/2/2/254/F1.large.jpg)
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis | American Society of Nephrology
![Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c07db4f1-f570-4aba-8367-9448fa2edf48/gr4_lrg.jpg)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet
![The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials | springermedizin.de The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials | springermedizin.de](https://media.springernature.com/lw400/springer-static/cover/journal/13300/12/1.jpg?as=jpg)
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials | springermedizin.de
![Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a7059c8f-f071-4a8c-9ebc-2f3090205f49/gr1.gif)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet
![PDF) Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes: A Comprehensive Review of the Dulaglutide Clinical Data Focusing on the AWARD Phase 3 Clinical Trial Program PDF) Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes: A Comprehensive Review of the Dulaglutide Clinical Data Focusing on the AWARD Phase 3 Clinical Trial Program](https://i1.rgstatic.net/publication/301592697_Efficacy_and_Safety_of_Dulaglutide_in_the_Treatment_of_Type_2_Diabetes_A_Comprehensive_Review_of_the_Dulaglutide_Clinical_Data_Focusing_on_the_AWARD_Phase_3_Clinical_Trial_Program/links/5e2416c1299bf1e1fabd4d67/largepreview.png)
PDF) Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes: A Comprehensive Review of the Dulaglutide Clinical Data Focusing on the AWARD Phase 3 Clinical Trial Program
![Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2) | SpringerLink Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-019-0646-y/MediaObjects/13300_2019_646_Fig3c_HTML.png)
Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2) | SpringerLink
![Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results - Clinical Therapeutics Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/56a72cf1-eb4a-4dda-ad59-cf4604abf289/gr1_lrg.jpg)
Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results - Clinical Therapeutics
![Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial – touchENDOCRINOLOGY Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial – touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2019/11/Doupis_F1.jpg)
Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial – touchENDOCRINOLOGY
![Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Louis Kuritzky, MD1; Guillermo Umpierrez, - ppt video online download Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Louis Kuritzky, MD1; Guillermo Umpierrez, - ppt video online download](https://slideplayer.com/slide/4129970/13/images/12/Dulaglutide%3A+Across+the+Type+2+Diabetes+Treatment+Continuum.jpg)
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes Louis Kuritzky, MD1; Guillermo Umpierrez, - ppt video online download
![Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4e495dbd-2bab-45a4-aa2b-39e53f55fd0d/gr3_lrg.gif)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial - The Lancet
![Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) - Virtual Meeting | EASD Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) - Virtual Meeting | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/eposters/480_593154_1/slide1.jpg)
Efficacy and safety of dulaglutide versus placebo and exenatide in type 2 diabetes (AWARD-1) - Virtual Meeting | EASD
![Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND - Virtual Meeting | EASD Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND - Virtual Meeting | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/1059_719722_2/Slide4AniShape1.jpg)
Exploring potential mediators of the cardiovascular benefit of dulaglutide in REWIND - Virtual Meeting | EASD
![Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial - The Lancet Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/1fa79a17-2a24-4aa4-b7d9-999aebe93056/gr1.jpg)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial - The Lancet
![Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting - Clinical Therapeutics Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/75998fb1-4658-4e5d-bc63-885362718efb/gr1_lrg.jpg)
Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting - Clinical Therapeutics
![Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial – touchENDOCRINOLOGY Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial – touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2019/11/Doupis_F2.jpg)
Once-weekly Dulaglutide and Major Cardiovascular Events—Results of the REWIND Trial – touchENDOCRINOLOGY
![Improvement in HbA1c in patients with type 2 diabetes mellitus treated with once weekly dulaglutide across baseline body mass index (BMI) subgroups at 26 or 52 weeks - Virtual Meeting | EASD Improvement in HbA1c in patients with type 2 diabetes mellitus treated with once weekly dulaglutide across baseline body mass index (BMI) subgroups at 26 or 52 weeks - Virtual Meeting | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/eposters/624_783625/preview.png)
Improvement in HbA1c in patients with type 2 diabetes mellitus treated with once weekly dulaglutide across baseline body mass index (BMI) subgroups at 26 or 52 weeks - Virtual Meeting | EASD
![Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment | SpringerLink Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-020-01561-1/MediaObjects/12325_2020_1561_Fig1_HTML.png)
Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment | SpringerLink
![Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program - Jendle - Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program - Jendle -](https://onlinelibrary.wiley.com/cms/asset/e0a97577-6e71-42e5-a4b1-36378887684c/dmrr2810-fig-0002-m.jpg)